National Taiwan University recently decided to establish a biomedical science park, with six specialized research centers, in Hsinchu. This project is directed at developing commercially viable treatments for chronic diseases. In a world of international commerce and the global spread of infectious diseases, this project seems out of touch with the reality of both the commercial and health situation at the present time.
Looking at how other nations are developing their health-care industry, we should realize that membership of the World Health Organization is of the greatest importance, for such an organization plays a significant role in global disease control and prevention programs. New industries seeking to become integrated in the international public health arena all focus on matters relating to the prevention of infectious diseases.
At the recent 58th World Health Assembly, many important resolutions had to do with infectious diseases, such as the control of malaria, articles relating to international health and prevention of a global pandemic.
Another important organization in the area of global prevention of infectious diseases is the Bill and Melinda Gates Foundation.
This foundation has raised US$450 million, and has, as of June, been providing funding to research teams from nine nations to make breakthroughs in a number of technologies with the potential to achieve global health goals. These include the Child Vaccine Program for the development of vaccines that do not require refrigeration or needles for administration, the development of gene or chemical agents to reduce or prevent bacteria propagation and 14 other major projects related to technologies for the treating of infectious diseases.
Taiwan's health industry must have a clear focus. If it wishes to follow the international mainstream in the areas of commerce and health care, then it should shift its focus toward infectious diseases.
If it wishes to continue to develop the industry for chronic disease treatment, then Taiwan must make a clear assessment of whether it has sufficient financial resources, a sufficiently advanced pharmaceutical industry, manufacturing capability and intellectual property rights protection to allow it to become a bio-tech power like Japan or Singapore.
Taiwan does not have a big share of the world pharmaceuticals market, and it only has to take one wrong step and it could end up being a marginal player in the global pharmaceuticals and bio-tech services market, or even as a dumping ground for second-rate products.
We must exercise the greatest possible care over the direction the Hsinchu Biomedical Science Park takes and how we define Taiwan's role in the global bio-tech market.
Chan Chang-chuan is the director of the Institute of Occupational Medicine and Industrial Hygiene at National Taiwan University.
Translated by Daniel Cheng and Ian Bartholomew
Could Asia be on the verge of a new wave of nuclear proliferation? A look back at the early history of the North Atlantic Treaty Organization (NATO), which recently celebrated its 75th anniversary, illuminates some reasons for concern in the Indo-Pacific today. US Secretary of Defense Lloyd Austin recently described NATO as “the most powerful and successful alliance in history,” but the organization’s early years were not without challenges. At its inception, the signing of the North Atlantic Treaty marked a sea change in American strategic thinking. The United States had been intent on withdrawing from Europe in the years following
My wife and I spent the week in the interior of Taiwan where Shuyuan spent her childhood. In that town there is a street that functions as an open farmer’s market. Walk along that street, as Shuyuan did yesterday, and it is next to impossible to come home empty-handed. Some mangoes that looked vaguely like others we had seen around here ended up on our table. Shuyuan told how she had bought them from a little old farmer woman from the countryside who said the mangoes were from a very old tree she had on her property. The big surprise
The issue of China’s overcapacity has drawn greater global attention recently, with US Secretary of the Treasury Janet Yellen urging Beijing to address its excess production in key industries during her visit to China last week. Meanwhile in Brussels, European Commission President Ursula von der Leyen last week said that Europe must have a tough talk with China on its perceived overcapacity and unfair trade practices. The remarks by Yellen and Von der Leyen come as China’s economy is undergoing a painful transition. Beijing is trying to steer the world’s second-largest economy out of a COVID-19 slump, the property crisis and
As former president Ma Ying-jeou (馬英九) wrapped up his visit to the People’s Republic of China, he received his share of attention. Certainly, the trip must be seen within the full context of Ma’s life, that is, his eight-year presidency, the Sunflower movement and his failed Economic Cooperation Framework Agreement, as well as his eight years as Taipei mayor with its posturing, accusations of money laundering, and ups and downs. Through all that, basic questions stand out: “What drives Ma? What is his end game?” Having observed and commented on Ma for decades, it is all ironically reminiscent of former US president Harry